467 related articles for article (PubMed ID: 15003450)
41. Novel human pathological mutations. Gene symbol: GLA. Disease: Fabry disease.
Niu DM; Lin HY; Chong KW; Hsu JH; Yu HC; Huang CH
Hum Genet; 2010 Jan; 127(1):122. PubMed ID: 20108436
[No Abstract] [Full Text] [Related]
42. Novel human pathological mutations. Gene symbol: GLA. Disease: Fabry disease.
Lin HY; Niu DM; Chong KW; Hsu JH; Yu HC; Huang CH
Hum Genet; 2010 Jan; 127(1):122-3. PubMed ID: 20108401
[No Abstract] [Full Text] [Related]
43. Interconversion of the specificities of human lysosomal enzymes associated with Fabry and Schindler diseases.
Tomasic IB; Metcalf MC; Guce AI; Clark NE; Garman SC
J Biol Chem; 2010 Jul; 285(28):21560-6. PubMed ID: 20444686
[TBL] [Abstract][Full Text] [Related]
44. Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene.
Garzuly F; Maródi L; Erdös M; Grubits J; Varga Z; Gelpi E; Rohonyi B; Mázló M; Molnár A; Budka H
Brain; 2005 Sep; 128(Pt 9):2078-83. PubMed ID: 15947062
[TBL] [Abstract][Full Text] [Related]
45. Cell-based screening of active-site specific chaperone for the treatment of Fabry disease.
Fan JQ; Ishii S
Methods Enzymol; 2003; 363():412-20. PubMed ID: 14579593
[No Abstract] [Full Text] [Related]
46. Structure-function relationships in alpha-galactosidase A.
Garman SC
Acta Paediatr; 2007 Apr; 96(455):6-16. PubMed ID: 17391432
[TBL] [Abstract][Full Text] [Related]
47. [Fabry-Anderson disease: current state of knowledge].
Vega-Vega O; Pérez-Gutiérrez A; Correa-Rotter R
Rev Invest Clin; 2011; 63(3):314-21. PubMed ID: 21888295
[TBL] [Abstract][Full Text] [Related]
48. Crystal structure of α-galactosidase from Lactobacillus acidophilus NCFM: insight into tetramer formation and substrate binding.
Fredslund F; Hachem MA; Larsen RJ; Sørensen PG; Coutinho PM; Lo Leggio L; Svensson B
J Mol Biol; 2011 Sep; 412(3):466-80. PubMed ID: 21827767
[TBL] [Abstract][Full Text] [Related]
49. Fabry disease: identification of 50 novel alpha-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations.
Shabbeer J; Yasuda M; Benson SD; Desnick RJ
Hum Genomics; 2006 Mar; 2(5):297-309. PubMed ID: 16595074
[TBL] [Abstract][Full Text] [Related]
50. Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female.
Rodríguez-Marí A; Coll MJ; Chabás A
Hum Mutat; 2003 Sep; 22(3):258. PubMed ID: 12938095
[TBL] [Abstract][Full Text] [Related]
51. Novel acceptor splice site mutation in the invariant AG of intron 6 of alpha-galactosidase A gene, causing Fabry disease. Mutations in brief no. 146. Online.
Matsumura T; Osaka H; Sugiyama N; Kawanishi C; Maruyama Y; Suzuki K; Onishi H; Yamada Y; Morita M; Aoki M; Kosaka K
Hum Mutat; 1998; 11(6):483. PubMed ID: 10200059
[TBL] [Abstract][Full Text] [Related]
52. Substrate specificity and mechanism from the structure of Pyrococcus furiosus galactokinase.
Hartley A; Glynn SE; Barynin V; Baker PJ; Sedelnikova SE; Verhees C; de Geus D; van der Oost J; Timson DJ; Reece RJ; Rice DW
J Mol Biol; 2004 Mar; 337(2):387-98. PubMed ID: 15003454
[TBL] [Abstract][Full Text] [Related]
53. Remarkable variability in renal disease in a large Slovenian family with Fabry disease.
Verovnik F; Benko D; Vujkovac B; Linthorst GE
Eur J Hum Genet; 2004 Aug; 12(8):678-81. PubMed ID: 15162124
[TBL] [Abstract][Full Text] [Related]
54. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
[TBL] [Abstract][Full Text] [Related]
55. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.
Ferri L; Guido C; la Marca G; Malvagia S; Cavicchi C; Fiumara A; Barone R; Parini R; Antuzzi D; Feliciani C; Zampetti A; Manna R; Giglio S; Della Valle CM; Wu X; Valenzano KJ; Benjamin R; Donati MA; Guerrini R; Genuardi M; Morrone A
Clin Genet; 2012 Mar; 81(3):224-33. PubMed ID: 21517827
[TBL] [Abstract][Full Text] [Related]
56. Kidney transplantation and enzyme alpha-galactosidase A therapy in patient with Fabry disease: a case report.
Dziemianko I; Jezior D; Boratyńska M; Patrzałek D; Kuźniar J; Szyber P; Klinger M
Transplant Proc; 2007 Nov; 39(9):2925-7. PubMed ID: 18022018
[TBL] [Abstract][Full Text] [Related]
57. [Alpha-galactosidase A gene mutation in a Chinese family with Fabry disease mimicking clinical features of hypertrophic cardiomyopathy].
Liu HJ; Cao KJ; Li CR; Dai J; Ma JZ; Yong YH; Sun W
Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Feb; 34(2):143-7. PubMed ID: 16626582
[TBL] [Abstract][Full Text] [Related]
58. 4-Phenylbutyrate rescues trafficking incompetent mutant alpha-galactosidase A without restoring its functionality.
Yam GH; Roth J; Zuber C
Biochem Biophys Res Commun; 2007 Aug; 360(2):375-80. PubMed ID: 17592721
[TBL] [Abstract][Full Text] [Related]
59. Fabry-database.org: database of the clinical phenotypes, genotypes and mutant α-galactosidase A structures in Fabry disease.
Saito S; Ohno K; Sakuraba H
J Hum Genet; 2011 Jun; 56(6):467-8. PubMed ID: 21412250
[TBL] [Abstract][Full Text] [Related]
60. Human gene mutations. Gene symbol: GLA. Disease: Fabry disease.
Lin WD; Hwu WL; Liu SC; Chen CP; Tsai FJ
Hum Genet; 2007 Sep; 122(2):212. PubMed ID: 18386366
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
